pharmaphorum May 8, 2024
Our round-up of recent biotech financings is headed by a sizeable $200 million third round for Zenas BioPharma, with Cellectis, Reunion Neuroscience, Karius, Context Therapeutics, and Enlaza also raising nine-figure sums.
Zenas said its Series C will keep the company ticking over as it works towards a series of readouts in clinical trials of its bifunctional monoclonal antibody obexelimab in autoimmune diseases.
The antibody, which binds to both CD19 and FcγRIIb and is designed to dampen down B-cell immune responses, is in a phase 3 trial in IGg4-related disease and a phase 2 study in warm autoimmune haemolytic anaemia, The cash injection follows a $118 million Series B in 2022 and will help to fund two further phase 2 studies...
Today's Sponsors
Today's Sponsor